Leaflet ETOPOSIDE-TEVA 20mg / ml concentrate for solution for infusion

Product code:
W52574002
Quantity:
1
Indicated for:
cancer
Route of administration:
infusion
Substance:
etoposide (topoisomerase inhibitor)
ATC
L01CB01 — Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Podophyllotoxin derivatives

Precautions:

Fertility warning

Fertility warning

This medicine may affect fertility.

Cytotoxic / special handling

Cytotoxic / special handling

Handle with special care.

Contraception required

Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding

Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy

Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity

Hepatotoxicity

This medicine may affect the liver.

Major drug interactions

Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis

Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring

Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests

Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions

Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Etoposide is a chemotherapy drug used to treat various types of cancer, including small cell lung cancer, testicular cancer, lymphomas, and leukemias. It belongs to a class of drugs called topoisomerase II inhibitors, which work by interfering with cell division, thereby destroying rapidly dividing cancer cells.

The mechanism of action of etoposide involves inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. By blocking this enzyme, etoposide causes the accumulation of DNA strand breaks, leading to cancer cell death. It is administered either intravenously or orally, depending on the type of cancer and the treatment protocol.

While effective, etoposide can cause side effects. The most common include nausea, vomiting, loss of appetite, hair loss, fatigue, and a decrease in blood cell counts (myelosuppression), which can increase the risk of infections, bleeding, and anemia. In rare cases, severe allergic reactions or other complications, such as secondary leukemia, may occur, especially with long-term use.

Etoposide must be administered under the strict supervision of an oncologist, and patients should be regularly monitored to assess their response to treatment and detect potential side effects. It is contraindicated in patients with hypersensitivity to the active substance or severe bone marrow suppression. During treatment, it is important for patients to avoid contact with sick individuals and follow their doctor's recommendations to minimize associated risks.

General data about ETOPOSIDE-TEVA 20mg / ml

Substance:
etoposide
Date of latest medicines list:
01-06-2026
Product code:
W52574002
Concentration:
20mg / ml
Pharmaceutical form:
concentrate for solution for infusion
Packing volume:
10 ml
Product type:
Generic medicine
Price:
154.10 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
PHARMACHEMIE BV - OLANDA
Holder:
TEVA PHARMACEUTICALS S.R.L. - ROMANIA
Number:
11908/2019/02
Shelf life:
3 years

Pharmaceutical forms available for etoposide

Concentrations available for etoposide

  • 100mg
  • 100mg/5ml
  • 200mg/10ml
  • 20mg/ml
  • 25mg
  • 50mg
  • 50mg/2.5ml

Compensation lists for ETOPOSIDE-TEVA 20mg / ml Teva

NHP 3 (C2) - NHP oncology

Price
154.10 RON
Copayment
151.04 RON
Patient
3.06 RON

NHP 9.1 (C2) - Spinal cord transplant

Price
154.10 RON
Copayment
151.04 RON
Patient
3.06 RON